Analyst Price Targets — SYRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 23, 2024 7:41 am | Edward Tenthoff | Piper Sandler | $5.00 | $2.47 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Syros Pharmaceuticals (SYRS) |
| June 26, 2024 7:48 am | Edward Tenthoff | Piper Sandler | $13.00 | $5.70 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Syros Pharmaceuticals (SYRS) |
| June 26, 2024 6:39 am | Andrew Fein | H.C. Wainwright | $15.00 | $5.70 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Syros Pharmaceuticals (SYRS) |
| August 9, 2022 6:22 pm | Mark Breidenbach | Oppenheimer | $30.00 | $9.27 | TheFly | Syros Pharmaceuticals price target lowered to $3 from $9 at Oppenheimer |
Latest News for SYRS
Institutional and Insider Ownership 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Profitability This table compares ADVANZ PHARMA and
Syros Pharmaceuticals (NASDAQ: SYRS - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Analyst Ratings This is a breakdown of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SYRS.
U.S. House Trading
No House trades found for SYRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.